Taiho Pharmaceutical Co. Ltd.’s US oncology division scored its first FDA approval Sept. 22 with early clearance of the oral fixed chemotherapy combination Lonsurf (trifluridine/tipiracil) in a very narrow indication for late-line treatment of metastatic colon cancer.
Taiho Oncology’s candidate (TAS-102) was approved for metastatic colorectal cancer (mCRC) in patients who already had fluoropyrimidine-, oxaliplatin- and irinotecan-...